Stimulation of the beta-2 adrenergic receptor for activating human brown adipose tissue
- Conditions
- Obesityoverweight1001842410013317
- Registration Number
- NL-OMON54946
- Lead Sponsor
- eids Universitair Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 10
White Caucasian males
Age between 18-35 years old
Lean (BMI >= 18 and <= 25 kg/m2)
- Diabetes mellitus (determined on basis of fasting glucose levels defined by
ADA criteria)
- Any other active endocrine disease (thyroid disease, any signs of Cushing*s
syndrome, adrenal disease and lipid-associated disorders such as familial
hypercholesterolemia)
- Any cardiac disease (i.e. ischemic cardiac disease, arrhythmias, severe heart
failure)
- A first-degree family member with sudden cardiac death
- Any chronic renal or hepatic disease
- Use of beta-adrenergic receptor agonists (for e.g. asthma)
- Use of medication known to influence glucose and/or lipid metabolism or brown
fat activity (e.g. beta-blockers, antidepressants, corticosteroids)
- Use of medication shown to increase risk on hypokalemia after salbutamol
administration (e.g. xanthine derivatives, steroids and diuretics)
- Any other contra-indications for the use of salbutamol or propranolol
- Abuse of alcohol or other substances
- Smoking
- Participation in an intensive weight-loss program or vigorous exercise
program during the last year before the start of the study
- Current participation in another research projects that may influence the
current research project
- Participation in another research in which a PET-CT scan was performed within
a year before the start of the current study
- Clinically relevant abnormalities in clinical chemistry or electrocardiogram
(ECG) at screening (to be judged by the study physician)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>- Glucose uptake by BAT, as measured by dynamic 18F-FDG PET/CT acquisition</p><br>
- Secondary Outcome Measures
Name Time Method <p>- Resting energy expenditure, as measured by indirect calorimetry<br /><br>- Serum markers for lipid metabolism (triglycerides (TG), total cholesterol<br /><br>(TC), high density lipoprotein-cholesterol (HDL-C), low density lipoprotein<br /><br>cholesterol (LDL-C), free fatty acids)<br /><br>- Lipid pathway analysis using lipidomic analysis in plasma samples<br /><br>- Serum markers for glucose metabolism (glucose, insulin)<br /><br>- Circulating plasma BAT markers (e.g. microRNAs)</p><br>